Stocks › ANIK

Anika Therapeutics, Inc.

ANIK·Nasdaq·United States United States·USD
$13.23
-0.05 (-0.38%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ANIK
Anika Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ANIKS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ANIK by members of U.S. Congress · 12 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Jul 1, 2022 Feb 26, 2020 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Aug 26, 2021 Feb 27, 2020 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Purchase
$50,001 - $100,000
Aug 26, 2021 Aug 1, 2019 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Aug 26, 2021 Oct 29, 2019 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Aug 26, 2021 Jan 28, 2020 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Aug 26, 2021 Jul 29, 2019 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Aug 26, 2021 Feb 28, 2020 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Mar 5, 2021 Mar 2, 2020 Filing ↗
Tom MalinowskiTom MalinowskiHouse · D · NJ ANIKAnika Therapeutics, Inc. · Stock Purchase
$15,001 -
Mar 5, 2021 Feb 26, 2020 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH ANIKAnika Therapeutics, Inc. · Stock Sale
$15,001 - $50,000
Jan 2, 2019 Dec 10, 2018 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH ANIKAnika Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Jul 7, 2017 Jun 28, 2017 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH ANIKAnika Therapeutics, Inc. · Stock Purchase
$15,001 - $50,000
Jan 5, 2017 Dec 28, 2016 Filing ↗

Whale Activity

Position changes in ANIK reported for 2026-09-30 by 151 institutional filers
Increased: 45New: 19Held: 20Decreased: 53Closed: 12No prior filing: 2
  • Increased45
  • New19
  • Held20
  • Decreased53
  • Closed12
  • No prior filing2
FilerSharesValueChange
Caligan Partners LP1.4M$28.2Mheld
BlackRock, Inc.1.4M$27.7Mdecreased
MORGAN STANLEY626.4K$12.3Mincreased
ACADIAN ASSET MANAGEMENT LLC606.5K$11.9Mheld
VANGUARD CAPITAL MANAGEMENT LLC565.9K$11.1Mdecreased
BOOTHBAY FUND MANAGEMENT, LLC529.6K$10.4Mdecreased
DIMENSIONAL FUND ADVISORS LP461.9K$9.1Mincreased
RENAISSANCE TECHNOLOGIES LLC458.7K$9.0Mdecreased
GEODE CAPITAL MANAGEMENT, LLC419.2K$8.2Mincreased
AQR CAPITAL MANAGEMENT LLC401.0K$7.9Mdecreased
CAPITAL MANAGEMENT CORP /VA379.4K$7.5Mdecreased
DEUTSCHE BANK AG\352.1K$6.9Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ANIK insiders, by quarter · Form 4
-20.0K-10.0K010.0K20.0K2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 17.2K2026 Q22026 Q3: 2,0002026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

673 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Fischetti Gary PDirector Purchase +1,000 $20.32 $20K Aug 4, 2026 Form 4 ↗
Fischetti Gary PDirector Purchase +1,000 $20.75 $21K Aug 3, 2026 Form 4 ↗
Fischetti Gary PDirector Grant / award +10.4K $0.00 $0 Jun 18, 2026 Form 4 ↗
HENNEMAN JOHN B IIIDirector Grant / award +10.4K $0.00 $0 Jun 18, 2026 Form 4 ↗
Richard StephenDirector Grant / award +10.4K $0.00 $0 Jun 18, 2026 Form 4 ↗
Capper Joseph HDirector Grant / award +10.4K $0.00 $0 Jun 18, 2026 Form 4 ↗
CONLEY SHERYL LDirector Grant / award +10.4K $0.00 $0 Jun 18, 2026 Form 4 ↗
Griffin Stephen D.President and CEO · Director Tax withholding −3,769 $14.41 $54K Jun 3, 2026 Form 4 ↗
Griffin Stephen D.President and CEO · Director Option exercise +12.8K — — Jun 3, 2026 Form 4 ↗
HENNEMAN JOHN B IIIDirector Purchase +5,000 $14.66 $73K May 1, 2026 Form 4 ↗
Griffin Stephen D.President and CEO · Director Purchase +12.2K $12.29 $150K Apr 30, 2026 Form 4 ↗
Colleran DavidEVP, General Counsel, Corp Sec Tax withholding −1,893 $14.20 $27K Mar 15, 2026 Form 4 ↗
Colleran DavidEVP, General Counsel, Corp Sec Option exercise +6,449 — — Mar 15, 2026 Form 4 ↗
Blanchard Cheryl RDirector Tax withholding −12.1K $14.20 $172K Mar 15, 2026 Form 4 ↗
Blanchard Cheryl RDirector Option exercise +25.1K — — Mar 15, 2026 Form 4 ↗
McLeod IanSVP, CAO & Treasurer Tax withholding −781 $14.20 $11K Mar 15, 2026 Form 4 ↗
McLeod IanSVP, CAO & Treasurer Option exercise +2,658 — — Mar 15, 2026 Form 4 ↗
Colleran DavidEVP, General Counsel, Corp Sec Tax withholding −4,168 $14.20 $59K Mar 14, 2026 Form 4 ↗
Colleran DavidEVP, General Counsel, Corp Sec Grant / award +4,694 $0.00 $0 Mar 14, 2026 Form 4 ↗
Colleran DavidEVP, General Counsel, Corp Sec Option exercise +9,388 — — Mar 14, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ANIK · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
397.8K$5.8M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
311.3K$4.6M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
123.7K$2.4M0.01%Jul 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
162.5K$2.4M0.00%Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account
College Retirement Equities Fund
142.3K$2.1M0.00%Jun 30, 2026
U.S. SMALL CAP VALUE PORTFOLIO
DFA INVESTMENT DIMENSIONS GROUP INC
86.7K$1.7M0.01%Jul 31, 2026
iShares Russell 2000 Value ETF
iShares Trust
104.9K$1.5M0.01%Jun 30, 2026
Schwab U.S. Small-Cap ETF
SCHWAB STRATEGIC TRUST
66.3K$1.4M0.01%Aug 31, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
65.8K$1.4M0.00%Aug 31, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
65.8K$1.4M0.01%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list ANIK's shares (CUSIP 035255108), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Vanguard Capital ManagementSCHEDULE 13G/A · passive (13G) · 659.2K shares5.0%
    Jul 31, 2026 · ↗
  • BlackRock Portfolio Management LLCSCHEDULE 13G/A · passive (13G) · 544.7K shares4.1%
    Jul 17, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming anika therapeutics as client
$0$25K$50K$75K$100K20252026 Q1: $30K2026 Q2: $30K2026 Q3: $30K2026
  • JK STRATEGIES, PUBLIC AFFAIRS ,LLCANIKA THERAPEUTICS INC · 2026 Q2$30K
    Filing ↗
  • JK STRATEGIES, PUBLIC AFFAIRS ,LLCANIKA THERAPEUTICS INC · 2026 Q1$30K
    Filing ↗
  • JK STRATEGIES, PUBLIC AFFAIRS ,LLCANIKA THERAPEUTICS INC · 2026 Q3$30K
    Filing ↗
  • JK STRATEGIES, PUBLIC AFFAIRS ,LLCANIKA THERAPEUTICS INC · 2025 Q1 · HCR—
    Filing ↗
  • KING & SPALDING LLPANIKA THERAPEUTICS, INC. · 2020 Q3—
    Filing ↗

Government Contracts

Federal awards to Anika Therapeutics, Inc. · USAspending

No federal contract awards found for Anika Therapeutics, Inc..

U.S. Patents

Recent USPTO applications naming Anika Therapeutics, Inc.

No USPTO patent applications found for Anika Therapeutics, Inc..

Annual Financials

From ANIK's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$112.8M$119.9M$120.8M$113.8M$147.8M
Operating income-$11.1M-$5.1M$844K$3.7M$2.6M
Net income-$10.9M-$56.4M-$82.7M-$14.9M$4.1M
Diluted EPS-$0.76-$3.83-$5.64-$1.02$0.28
Operating cash flow$11.2M$5.4M-$1.8M$4.4M$8.4M
Cash and equivalents$57.5M$55.6M$68.7M$86.3M$94.4M
Total assets$190.3M$202.7M$270.6M$349.1M$347.5M
Shareholders' equity$143.5M$154.0M$212.3M$285.6M$287.1M

As Anika Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 3, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in ANIK's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 6, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 29, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationJul 14, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 23, 2026
    EDGAR ↗

About Anika Therapeutics, Inc.

From SEC EDGAR company records
Industry (SIC 3841)Surgical & Medical Instruments & Apparatus
SectorHealthcare
HeadquartersBEDFORD, MA
IncorporatedDE
Former namesANIKA THERAPEUTICS INC, ANIKA RESEARCH INC